Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

Medivir AB. (2/9/17). "Press Release: Christine Lind New CEO of Medivir AB Effective 1 April 2017". Stockholm.

Organisation Organisation Medivir AB (Nasdaq Stockholm: MVIR)
  Today Medivir (Group)
  Group Medivir (Group)
Products Product cancer drug
  Product 2 drug development
Persons Person Lind, Christine (Medivir 201704– CEO before EVP Strategic BusDev before LifeCellCorp + Merrill Lynch/BoAML in NY)
  Person 2 Prager, Niklas (Medivir 201409–201704 CEO before Merck & Co + Pfizer AB + Envirotainer AB + Qbtech AB LEFT 4/17)

Medivir AB (Nasdaq Stockholm: MVIR) announces today that Christine Lind has been appointed as the new CEO of Medivir AB. She succeeds Niklas Prager, who accepted the role as CEO in 2014 from a position as a Director of the Board when the company faced the need of a corporate transformation. Christine Lind will take up her new position on 1 April 2017, until which time she will continue in her existing role as EVP Strategic Business Development. Niklas Prager will continue as CEO until 1 April and will also make himself available to Christine until the Annual General Meeting on 3 May, in order to ensure an optimal and smooth transition.

“I am delighted and proud that we have, in Christine Lind, an internal candidate who can take over the role of CEO, thereby ensuring continuity in the new operational focus and a controlled handover,” says Chairman of the Board, Anna Malm Bernsten. “Christine has been instrumental in our transformation and has extensive and in-depth experience. I am convinced that she, in partnership with the rest of the management team and all of the company’s highly skilled employees, has precisely the qualities needed to maximise the potential of the new Medivir’s broad and extremely exciting pipeline with its focus on oncology,” continues Anna Malm Bernsten. “I would also like to thank Niklas Prager for the far-reaching transformation programme that he has implemented so successfully while simultaneously distributing SEK 1.5 billion to our shareholders.”

“It feels natural to hand over to someone new now that we have completed the comprehensive transformation process that has been my primary task over the past years. Today’s Medivir is a completely new company that is strongly positioned and has fantastic potential for value creation over the next few years. I am also very pleased by the fact that, in Christine, we have secured a strong internal candidate who can take over as CEO,” says Niklas Prager the outgoing CEO.

Christine Lind has been Medivir’s EVP Strategic Business Development since 2015, prior to which she was VP Business Development at LifeCell Corporation in New Jersey, and has spent the majority of her career at Merrill Lynch & Co. / Bank of America Merrill Lynch in New York, where she specialised in Healthcare Investment Banking. Christine, who was born in 1974, is a US citizen and holds a B.Sc. in Finance and Information Systems from New York University and an MBA in Finance and Management from Columbia Business School.

“I am absolutely delighted to take over the role of CEO for Medivir AB. It is an honour to be entrusted to lead the talented Medivir organization. I feel very confident that the strong R&D portfolio and the focus Medivir has will deliver value to our shareholders in the coming years,” says Christine Lind, CEO Designate of Medivir AB.

For further information, please contact:
Niklas Prager, outgoing CEO of Medivir AB, mobile +46 768117744
Christine Lind, CEO Designate of Medivir AB, mobile +46 727102205
Anna Malm Bernsten, Chairman of the Board of Medivir AB, mobile +46 705598541

This information is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 13.00 CET on 9 February 2017.

About Medivir

Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Medivir (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top